TL;DR: Valink Therapeutics is a Y Combinator Winter 2021 startup Discovering bispecific antibody drug-conjugates (BsADC) against cancer, currently active with a team of 15.
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Last verified:
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
Built by LemStudio
Yes. Valink Therapeutics was funded by Y Combinator in the Winter 2021 batch. Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single disco…
Valink Therapeutics was part of Y Combinator's Winter 2021 batch.
Valink Therapeutics has a team of 15 people according to Y Combinator's directory.
Valink Therapeutics is currently listed as Active with a team of 15 in Y Combinator's directory.
Loading interactive view…